News -
Check out the posts below to learn the latest updates on our progress
- February 16 2021EXUMA Biotech on NPR’s TechNation with Dr. Moira Gunn
TechNation Radio
- February 5 2021Economically Viable, Same-Day Autologous Cell Therapies
Pharma's almanac
- January 11 2021EXUMA Biotech Announces Collaboration with Moffitt Cancer Center for the Development of a Rapid-Point-Of-Care SC CAR-T ProgramPR Newswire
- November 11 2020EXUMA Biotech Presents Preclinical Data on Rapid Point-of-Care “rPOC” Subcutaneous CAR-T Platform at the SITC 35th Anniversary Annual Meeting & Pre-Conference
PR Newswire
- November 9 2020Rapid point-of-care subcutaneous CAR-T from blood draw to injection in 4 hours with modified LV encoding CARs and synthetic driver elements enables efficient CAR-T expansion and tumor regression
SITC 35th Anniversary Annual Meeting & Pre-Conference (virtual)
- October 19 2020Logic-gating HER2 CAR-T to the tumor microenvironment mitigates on-target, off-tumor toxicity without compromising cytotoxicity against HER2-over-expressing tumors
AACR Tumor Immunology & Immunotherapy 2020
- October 19 2020Dr. Sid Kerkar Joins EXUMA Biotech as Vice President Oncology, R&D, Company Presents Data on HER2-Targeting CAR-T at AACR Tumor Immunology and Immunotherapy ConferencePR Newswire
- October 7 2020Communicating Your Strategic Plan
CFO Thought Leader
- September 24 2020Speeding the Delivery of CAR-T Therapies While Cutting the Cost
The BIO Report
- August 10 2020Expanding Access to CAR-T: Dr. Greg Frost
PharmExec.com